XPENG
10.3.2022 14:02:20 CET | Business Wire | Press release
XPENG (the “Company”, NYSE: XPEV and HKEX: 9868), a leading smart mobility and technology company, today kicks off customer reservations of its third and latest production model on the market, the XPENG P5 smart EV sedan, simultaneously in Denmark, the Netherlands, Norway and Sweden. The move marks a major milestone in its European expansion plans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005596/en/
XPENG today is also opening its first XPENG Experience Store in the Netherlands, its second branded showroom in Europe, following the opening of the Stockholm XPENG Experience Store in Sweden last month.
The XPENG P5 is the Company’s first model to be made available simultaneously in four European markets. The customer reservation process is fully-digitized, and accessible immediately in each of these four markets, both via the XPENG official websites in each country, and the XPENG mobile APP launched earlier this week.
“The XPENG P5’s arrival in four key European markets is a new demonstration of our commitment to Europe,” said Leon He, Vice President of XPENG. “Each new XPENG model achieves a new level of technology sophistication. The P5 brings a host of differentiated features to a new customer base in Europe, a market where we are building ourselves as a long-term player,” said Mr. He.
The XPENG P5 – Intelligence that moves you
The XPENG P5, a mid-size family sedan, is equipped with version 2.5 of XPENG’s in-house developed Advanced Driver Assistance System (XPILOT), and its intelligent in-car operating system - Xmart OS. The P5 combines the advanced level of driver assistance with superior passenger comfort and convenience. Through firmware over-the-air (OTA) upgrades, the P5 will bring new features and optimized functions to customers on a continuous basis.
The sleek aerodynamic profile of the P5 with a large panoramic canopy glass sunroof, neat fastback and unobtrusive ducktail gives it a driving range of 465 km WLTP, powered by a battery of 66 kWh capacity.
The Xmart OS provides comprehensive cockpit and interior function management, with a 12.3-inch LCD dashboard, a 15.6-inch FHD high resolution (1920 * 1080) large center display, in-car voice control capable of distinguishing between driver and passenger positions, and a library of in-car Apps to assist, inform, and entertain driver and passengers.
This intelligent cockpit management is integrated into the stylish interior fittings, with heated leatherette seats, the Xfreebreath intelligent air purification system and advanced surround sound system. Many vehicle functions can also be accessed via mobile phone remote control.
For added convenience, the P5 incorporates 26 storage compartments and a 450L large trunk, plus an additional 70L compartment underneath.
XPENG experience store starts operation in the Netherlands
Concurrently, XPENG is also opening its first experience store in the Westfield Mall of the Netherlands in Leidschendam, conveniently close to major conurbations such as Rotterdam and The Hague. As well as the XPENG P5, the XPENG smart sports sedan P7, and the prototype of its flying vehicle XPENG X2 are also on display in the Westfield Mall experience store, demonstrating the brand’s vision of future mobility and its spirit of exploration.
Customers can make online reservations for XPENG P5 from today. The test drive will be available in April 2022.
Two additional stores in the Netherlands will open later this year in collaboration with XPENG's local partner Emil Frey, and the Company plans to open more stores in major cities across the Netherlands over the next few years.
XPENG P5 Specs
Dimension |
|
Length x Width x Height (mm) |
4808mm / 1840mm / 1520mm |
Wheelbase (mm) |
2768mm |
Seats |
5 |
Curb Weight (kg) |
1715Kg |
Cargo Space |
520 L |
Performance |
|
Type of Drive |
Front-wheel drive |
Battery Capacity (kWh) |
66 kWh |
WLTP Driving Range (km) |
465 Km |
XPILOT 2.5 (ADAS) |
|
High-definition Millimeter Wave Radar |
5 |
Ultrasonic Wave Sensors |
12 |
Autonomous Driving Surround View Camera |
4 |
Autonomous Driving High Perception Camera |
9 |
XPILOT Safety |
● |
XPILOT Driving |
● |
XPILOT Parking |
● |
Xmart OS In-car Intelligent System |
|
15.6" Central Touch Screen Display |
● |
12.3" HD Liquid Crystal Intelligent Instrument Panel |
● |
Mobile App Remote Control |
● |
"Hey XPENG" Voice Assistant |
● |
Firmware over-the-air software updates |
● |
Exterior |
|
Lightsaber 3.0 LED Lights |
● |
Lightsaber 3.0 LED DRL |
● |
Panoramic Sunroof |
● |
215/55R18 Michelin Tyre |
● |
About XPENG
XPENG is a leading smart mobility company founded with a mission to explore and drive smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley and San Diego. In 2021, XPENG established its European headquarters in the Netherlands, and is expanding its presence in Sweden, Norway and Denmark. XPENG's smart EVs are manufactured at its fully-owned plant in Zhaoqing, Guangdong Province, China. For more information, please visit: www.heyxpeng.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom